2210314-30-8
2210314-30-8
Chemical Structure
Olendalizumab
Synonym(s): ALXN1007; Lendalizumab
- CAS No.: 2210314-30-8
- Formula:N/A
- Molecular Weight:(146 kDa)
SMILES: [Olendalizumab]
Biological Activity: Olendalizumab (ALXN1007) is a mouse-derived and humanized IgG2-G4-κ antibody, targeting to Complement protein C5a (Ki=60 pM). Olendalizumab targets the complement inflammatory pathway. Moreover, Olendalizumab can be used for research of complement mediated disorder caused by corona virus[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Olendalizumab | 97.43% | Olendalizumab (ALXN1007) is a mouse-derived and humanized IgG2-G4-κ antibody, targeting to Complement protein C5a (Ki=60 pM). Olendalizumab targets the complement inflammatory pathway. Moreover, Olendalizumab can be used for research of complement mediated disorder caused by corona virus. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Dysinger M, et al. A Gyrolab Assay for the Quantitation of Free Complement Protein C5a in Human Plasma. AAPS J. 2018 Oct 2;20(6):106. [Content Brief]
- [2]. Annane D, et al. Methods for treating a complement mediated disorder caused by viruses. World Intellectual Property Organization, WO2021211940 A1. 2021-10-21.
Keywords
